Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2020 / N 4

Особенности поражения сердечно-сосудистой системы при коронавирусной инфекции. Место β-адреноблокаторов и блокаторов кальциевых каналов
Ю.А. Карпов, И.А. Комиссаренко

References

1. Varejão Strabelli TM, Uip DE. COVID-19 and the heart. Arquivos Brasileiros de Cardiologia 2020 Apr;114(4):598-600.
2. Yavelov IS. COVID-19 and cardiovascular diseases. International Heart and Vascular Disease Journal 2020;8(27):4-13 (In Russian).
3. European Society of Cardiology. ESC Guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Last updated on 10 June 2020. Available from: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance Accessed 2021 Jun 10.
4. Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, Italia L, Zaccone G, Tedino C, Fabbricatore D, Curnis A, Faggiano P, Gorga E, Lombardi C, Milesi G, Vizzardi E, Volpini M, Nodari S, Specchia C, Maroldi R, Bezzi M, Metra M. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. European Heart Journal 2020 May;41(19):1821-9.
5. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BM, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR, Salazar-Schicchi J, Yip NH, Brodie D, O’Donnell MR. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet 2020 Jun;395(10239):1763-70.
6. Karpov YuA. Treatment of patients with stable angina: to New recommendation release of the All-Russian Scientific Society of Cardiology. Russian Medical Journal 2008;16(21):1379-81 (In Russian).
7. Ministry of Healthcare of the Russian Federation; Russian Society of Cardiology. Clinical recommendations. Arterial hypertension in adults. ICD-10: I10, I11, I12, I13, I15. Year of approval: 2020. Age category: adults. Expiration date: 2022. Moscow, 2020. 107 p. Available from: http://cr.rosminzdrav.ru/#!/schema/687 Accessed 2021 Jun 10. (In Russian).
8. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension 2018 Oct;36(10):1953-2041.
9. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018 Sep;39(33):3021-104.
10. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal 2020 Jan;41(3):407-77.
11. Ministry of Healthcare of the Russian Federation; Russian Society of Cardiology. Clinical recommendations. Stable ischemic heart disease. ICD 10: I20. 0, I20. 1, I20. 8, I20. 9, I25. 0, I25. 1, I25.2, I25.3, I25.4, I25.5, I25.6, I25.8, I25.9. Age category: adults. Year of approval: 2020. Moscow, 2020. 114 p. Available from: http://cr.rosminzdrav.ru/#!/recomend/133 Accessed 2021 Jun 10. (In Russian).
12. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 Sep;102(13):1503-10.
13. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004 Nov;292(18):2217-25.
14. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet 2005;366:895-906.
15. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O’Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 Mar;113(9):1213-25.
16. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood J, Jafri SZA, Proschan MA, Thadani U, Whelton PK, Wright JT; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006 Sep;48(3):374-84.
17. Shlyakhto EV, Konradi AO, Arutyunov GP, Arutyunov AG, Bautin AE, Boytsov SA, Villevalde SV, Grigoryeva NYu, Duplyakov DV, Zvartau NE, Koziolova NA, Lebedev DS, Malchikova SV, Medvedeva EA, Mikhaylov EN, Moiseyeva OM, Orlova YaA, Pavlova TV, Pevzner DV, Petrova MM, Rebrov AP, Sitnikova MYu, Solovyeva AE, Tarlovskaya EI, Trukshina MA, Fedotov PA, Fomin IV, Khripun AV, Chesnikova AI, Shaposhnik II, Yavelov IS, Yakovlev AN. Guidelines for diagnosis and treatment of circulatory diseases in context of COVID-19 pandemic. Russian Journal of Cardiology 2020;25(3):129-48 (In Russian).
18. Crespi B, Alcock J. Conflicts over calcium and the treatment of COVID-19. Evolution, Medicine, and Public Health 2021 Nov;9(1):149-56.
19. Straus MR, Bidon M, Tang T, Whittaker GR, Daniel S. FDA approved calcium channel blockers inhibit SARS-CoV-2 infectivity in epithelial lung cells. bioRxiv 2020. Available from: https://doi.org/10.1101/2020.07.21.214577 Accessed 2021 Jun 10.
20. Zhang LK, Sun Y, Zeng H, Wang Q, Jiang X, Shang X, Wu Y, Li S, Zhang Y-L, Hao Z-N, Chen H, Jin R, Liu W, Li H, Peng K, Xiao G. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discovery 2020;(6):96. Available from: https://www.nature.com/articles/s41421-020-00235-0.pdf?origin=ppub Accessed 2021 Jun 10.
21. Bhatla A, Mayer MM, Adusumalli S, Hyman MC, Oh E, Tierney A, Moss J, Chahal AA, Anesi G, Denduluri S, Domenico CM, Arkles J, Abella BS, Bullinga JR, Callans DJ, Dixit S, Epstein AE, Frankel DS, Garcia FC, Kumareswaram R, Nazarian S, Riley MP, Santangeli P, Schaller RD, Supple GE, Lin D, Marchlinski F, Deo R. COVID-19 and cardiac arrhythmias. Heart Rhythm 2020 Sep;17(9):1439-44.
22. Vasanthakumar N. Beta-adrenergic blocker treatment as a potential treatment for COVID-19 patients. BioEssays 2020 Nov;42(11):e2000094.
23. Park CS, Lee HY. Clinical utility of sympathetic blockade in cardiovascular disease management. Expert Review of Cardiovascular Therapy 2017 Mar;15(4):277-88.
24. Al-Qadi MO, Kashyap R. Effect of chronic beta blockers use on sepsis-related acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 2015;191:A1602.
25. Noveanu M, Breidthardt T, Reichlin T, Gayat E, Potocki M, Pargger H, Heise A, Meissner J, Twerenbold R, Muravitskaya N, Mebazaa A, Mueller C. Effect of oral beta-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. Critical Care (London, England) 2010;14(6):R198.
26. Pinto-Sietsma SJ, Flossdorf M, Buchholz VR, Offerhaus J, Bleijendaal H, Beudel M, Volders PGA, Ter Bekke RMA, Dormans T, Zwetsloot PP, de Jager P, Massberg S, Rämer P, Wendtner C, Hoffmann E, Rothe K, Feihl S, Kessler T, Pinto YM, Schunkert H. Antihypertensive drugs in COVID-19 infection. European Heart Journal. Cardiovascular Pharmacotherapy 2020 Nov;6(6):415-6.
27. Vasanthakumar N. Can beta-adrenergic blockers be used in the treatment of COVID-19? Medical Hypotheses 2020 Sep;142:109809.
28. Tan K, Harazim M, Tang B, Mclean A, Nalos M. The association between premorbid beta blocker exposure and mortality in sepsis – a systematic review. Critical Care (London, England) 2019 Sep;23(1):298.
29. Heriansyah T, Nur Chomsy I, Febrianda L, Hadi TJ, Wihastuti TA. The potential benefit of beta-blockers for the management of COVID-19 protocol therapy-induced QT prolongation: a literature review. Scientia Pharmaceutica 2020 Nov;88(4):55.
30. Karpov YuA, Shubina AT. Role of beta-blockers in reducing sympathetic tone in patients with arterial hypertension. Atmosphere. Cardiology News 2018;3:3-9 (In Russian).
31. Kukes VG, Ostroumova OD, Mamayev VI, Vatutina AM, Abakumov YuE, Zykova AA. Efficacy and safety of various beta-blockers in patients with isolated systolic hypertension and concomitant diabetes mellitus and obstructive pulmonary disease. Therapeutic Archive 2003;75(8):43-7 (In Russian).
32. Karpov YuA, Shubina AT. Beta-blockers in treatment of patients with arterial hypertension: new opportunities and prospects. Russian Medical Journal 2005;13(19):1265-9 (In Russian).
33. Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respiratory Research 2021 Feb;22(1):64.
34. Gulea C, Zakeri R, Quint JK. Effect of beta-blocker therapy on clinical outcomes, safety, health-related quality of life and functional capacity in patients with chronic obstructive pulmonary disease (COPD): a protocol for a systematic literature review and meta-analysis with multiple treatment comparison. BMJ Open 2018 Nov;8(11):e024736.
35. Mandiricha T, Rochmanti M. A novel pleiotropic effect of beta-blockers: useful or not? Systematic Reviews in Pharmacy 2020 Sep-Oct;11(9):178-86.
36. COVID-19 Drug Interactions. Liverpool Drug Interactions Group. Detailed recommendations for interactions with experimental COVID-19 therapies. Updated 19 April 2021. Available from: https://www.covid19-druginteractions.org Accessed 2021 Jun 2021.
37. Yan F, Huang F, Xu J, Yang P, Qin Y, Lv J, Zhang S, Ye L, Gong M, Liu Z, Wei J, Xie T, Xu KF, Gao GF, Wang FS, Cai L, Jiang C. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discovery 2020 Oct 29;6(1):77.
38. Solaimanzadeh I. Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19. Cureus. 2020 May 12;12(5):e8069.
39. Singh S, Widrich C, Nap M, Schokker E, Zwinderman AH, Pinto-Sietsma SJ. Antihypertensives and their relation to mortality by SARS-CoV-2 infection. Journal of Medical Virology 2021 Apr;93(4):2467-75.
40. Grinevich VB, Gubonina IV, Doshchitsin VL, Kotovskaya YuV, Kravchuk YuA, Ped VI, Sas EI, Syrov AV, Tarasov AV, Tarzimanova AI, Tkacheva ON, Trukhan DI. Management of patients with comorbidity during novel coronavirus infection (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention 2020;19(4):135-72 (In Russian).
41. Ma C, Cong Y, Zhang H. COVID-19 and the digestive system. The American Journal of Gastroenterology 2020 Jul;115(7):1003-6.
42. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 46. 2020. Available from: https://apps.who.int/iris/handle/10665/331443 Accessed 2021 Jun 10.
43. Yang F, Liu N, Hu JY, Wu LL, Su GS, Zhong NS, Zheng ZG. [Pulmonary rehabilitation guidelines in the principle of 4S for patients infected with 2019 novel coronavirus (2019-nCoV)]. Zhonghua Jie He He Hu Xi Za Zhi 2020 Mar;43(3):180-2.
44. Yang F, Liu N, Wu JY, Hu LL, Su GS, Zheng NS. [Pulmonary rehabilitation guidelines in the principle of 4S for patients infected with 2019 novel coronavirus (2019-nCoV)]. Zhonghua Jie He He Hu Xi Za Zhi 2020 Feb;43(0):E004.
45. Barker-Davies RM, O’Sullivan O, Senaratne KPP, Baker P, Cranley M, Dharm-Datta S, Ellis H, Goodall D, Gough M, Lewis S, Norman J, Papadopoulou T, Roscoe D, Sherwood D, Turner P, Walker T, Mistlin A, Phillip R, Nicol AM, Bennett AN, Bahadur S. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. British Journal of Sports Medicine 2020 Aug;54(16):949-59.
46. Shmonin AA, Maltseva MN, Melnikova EV, Mishina IE, Ivanova GE. Medical rehabilitation in coronavirus infection: new challenges for physical and rehabilitation medicine in Russia. Bulletin of Rehabilitation Medicine 2020;97(3):14-21 (In Russian).
47. Asly M, Hasim A. Rehabilitation of post-COVID-19 patients. The Pan African Medical Journal 2020 Jul;36:168.
48. Haute Autorité de Santé (HAS). HAS. Rapid responses in the context of COVID-19-Management of post-COVID-19 patients in Physical Medicine and Rehabilitation units (MPR), and on return home. Validated by the HAS Board on 16 April 2020.
49. Bubnova MG, Aronov DM. COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. Pulmonologiya 2020;30(5):688-99 (In Russian).
50. Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A review of Persistent Post-COVID Syndrome (PPCS). Clinical Reviews in Allergy & Immunology 2021 Feb 20;1-9. doi: 10.1007/s12016-021-08848-3. Online ahead of print.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]